Principal Financial Group Inc Biotechnology

Principal Financial Group Inc

$167 Billion
Q1 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
BPMC Blueprint Medicines Corp	$7.64B	$1.42 Million 0.0% of portfolio	16,078	Q1 2025 Reduced 0.65%
VCYT Veracyte, Inc.	$1.99B	$1.06 Million 0.0% of portfolio	35,663	Q1 2025 Added 9.53%
MNKD Mannkind Corp	$1.11B	$1.01 Million 0.0% of portfolio	200,445	Q1 2025 Added 8.6%
ARDX Ardelyx, Inc.	$612M	$732,000 0.0% of portfolio	149,174	Q1 2025 Added 0.7%
XERS Xeris Biopharma Holdings, Inc.	$617M	$624,000 0.0% of portfolio	113,746	Q1 2025 Added 0.47%
RPRX Royalty Pharma PLC	$14.7B	$590,000 0.0% of portfolio	18,970	Q1 2025 Reduced 5.7%
MDGL Madrigal Pharmaceuticals, Inc.	$4.69B	$474,000 0.0% of portfolio	1,434	Q1 2025 Reduced 6.27%
MDXG Mimedx Group, Inc.	$720M	$467,000 0.0% of portfolio	61,451	Q1 2025 Added 2.03%
RVMD Revolution Medicines, Inc.	$3.56B	$452,000 0.0% of portfolio	12,792	Q1 2025 Added 2.07%
IONS Ionis Pharmaceuticals Inc	$5.22B	$315,000 0.0% of portfolio	10,447	Q1 2025 Reduced 23.27%
PTCT Ptc Therapeutics, Inc.	$3.7B	$297,000 0.0% of portfolio	5,840	Q1 2025 Reduced 1.93%
RNA Avidity Biosciences, Inc.	$1.86B	$267,000 0.0% of portfolio	9,070	Q1 2025 Reduced 4.02%
HRTX Heron Therapeutics, Inc.	$247M	$253,000 0.0% of portfolio	115,318	Q1 2025 Added 1.55%
ACLX Arcellx, Inc.	$2.85B	$229,000 0.0% of portfolio	3,495	Q1 2025 Reduced 5.0%
SRRK Scholar Rock Holding Corp	$1.83B	$202,000 0.0% of portfolio	6,302	Q1 2025 Reduced 0.68%
FOLD Amicus Therapeutics, Inc.	$1.69B	$191,000 0.0% of portfolio	23,419	Q1 2025 Reduced 6.75%
BCRX Biocryst Pharmaceuticals Inc	$2.07B	$123,000 0.0% of portfolio	16,495	Q1 2025 Reduced 7.37%
RXRX Recursion Pharmaceuticals, Inc.	$825M	$106,000 0.0% of portfolio	20,069	Q1 2025 Reduced 6.0%
YMAB Y M Abs Therapeutics, Inc.	$223M	$99,000 0.0% of portfolio	22,434	Q1 2025 Added 1.07%
OCUL Ocular Therapeutix, Inc	$664M	$92,000 0.0% of portfolio	12,623	Q1 2025 Reduced 5.94%
AUPH Aurinia Pharmaceuticals Inc.	$1.16B	$81,000 0.0% of portfolio	10,156	Q1 2025 Reduced 1.55%
NVAX Novavax Inc	$580M	$76,000 0.0% of portfolio	11,913	Q1 2025 Reduced 2.25%
GERN Geron Corp	$589M	$71,000 0.0% of portfolio	44,857	Q1 2025 Added 0.66%
ABUS Arbutus Biopharma Corp	$517M	$40,000 0.0% of portfolio	11,528	Q1 2025 Reduced 10.05%
IBRX Immunity Bio, Inc.	$1.38B	$34,000 0.0% of portfolio	11,421	Q1 2025 Reduced 1.48%
AKBA Akebia Therapeutics, Inc.	$632M	$27,000 0.0% of portfolio	14,317	Q1 2025 Added 17.15%
NUVB Nuvation Bio Inc.	$539M	$20,000 0.0% of portfolio	11,758	Q1 2025 Added 15.97%
TSHA Taysha Gene Therapies, Inc.	$140M	$19,000 0.0% of portfolio	13,989	Q1 2025 Reduced 6.56%
ERAS Erasca, Inc.	$192M	$17,000 0.0% of portfolio	12,522	Q1 2025 Added 23.54%
OCGN Ocugen, Inc.	$206M	$15,000 0.0% of portfolio	21,630	Q1 2025 Reduced 2.77%
NKTR Nektar Therapeutics	$126M	$7,000 0.0% of portfolio	11,454	Q1 2025 Added 6.38%
LCTX Lineage Cell Therapeutics, Inc.	$112M	$5,000 0.0% of portfolio	12,740	Q1 2025 Reduced 7.01%
LYEL Lyell Immunopharma, Inc.	$2.84B	$5,000 0.0% of portfolio	10,997	Q4 2024 New
MRSN Mersana Therapeutics, Inc.	$36.9M	$3,000 0.0% of portfolio	10,354	Q1 2025 New
XFOR X4 Pharmaceuticals, Inc	$272M	$3,000 0.0% of portfolio	13,720	Q1 2025 Reduced 5.32%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.